Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

Diagnostic Values Of Soluble Mesothelin-related Peptides For Malignant Pleural Mesothelioma: Updated Meta-analysis

Ai Cui, Xiao-guang Jin, Kan Zhai, Z. Tong, H. Shi
Published 2014 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
Objective Although the values of soluble mesothelin-related peptides (SMRPs), including mesothelin and megakaryocyte potentiating factor, in serum and/or pleural fluid for diagnosing malignant pleural mesothelioma (MPM) have been extensively studied, the exact diagnostic accuracy of these SMRPs remains controversial. The purpose of the present meta-analysis is to update the overall diagnostic accuracy of SMRPs in serum and, furthermore, to establish diagnostic accuracy of SMRPs in pleural fluid for MPM. Design Systematic review and meta-analysis. Methods A total of 30 articles of diagnostic studies were included in the current meta-analysis. Sensitivity, specificity and other measures of accuracy of SMRPs in serum and pleural fluid for the diagnosis of MPM were pooled using random effects models. Summary receiver operating characteristic curves were used to summarise overall test performance. Results The summary estimates of sensitivity, specificity, positive likelihood ratio, negative likelihood ratio and diagnostic OR were 0.61, 0.87, 5.71, 0.43 and 14.43, respectively, for serum and 0.79, 0.85, 4.78, 0.30 and 19.50, respectively, for pleural fluid. It was also found that megakaryocyte potentiating factor in serum had a superior diagnostic accuracy compared with mesothelin for MPM. Conclusions SMRPs in both serum and pleural fluid are helpful markers for diagnosing MPM with similar diagnostic accuracy. The negative results of SMRP determinations are not sufficient to exclude non-MPM, and the positive test results indicate that further invasive diagnostic steps might be necessary for the diagnosis of MPM.
This paper references
10.1097/JTO.0b013e31828f696b
Combination of Mesothelin and CEA Significantly Improves the Differentiation between Malignant Pleural Mesothelioma, Benign Asbestos Disease, and Lung Cancer
T. Muley (2013)
10.1136/thx.2007.077958
Diagnostic accuracy of tumour markers for malignant pleural effusion: a meta-analysis
Q-L Liang (2007)
10.3233/DMA-2011-0866
Soluble Mesothelin-Related Peptides Levels in Patients with Malignant Mesothelioma
A. Franko (2012)
10.1158/1078-0432.CCR-05-1477
Detection and Quantitation of Serum Mesothelin, a Tumor Marker for Patients with Mesothelioma and Ovarian Cancer
R. Hassan (2006)
10.1007/s12032-013-0649-x
Clinical value of mesothelin in pleural effusions versus histology by medical thoracoscopy: brief report
P. Canessa (2013)
10.1200/JCO.2009.26.9944
Soluble mesothelin-related Peptide and osteopontin as markers of response in malignant mesothelioma.
P. Wheatley-Price (2010)
10.3892/ETM_00000048
Soluble mesothelin-related protein in pleural effusion from patients with malignant pleural mesothelioma.
N. Fujimoto (2010)
10.1043/1543-2165-133.8.1317
Guidelines for pathologic diagnosis of malignant mesothelioma: a consensus statement from the International Mesothelioma Interest Group.
A. Husain (2009)
10.1016/J.LUNGCAN.2007.08.030
Non-invasive diagnosis of pleural malignancies: the role of tumour markers.
M. Van den Heuvel (2008)
10.1164/rccm.200807-1125OC
Kinetics of soluble mesothelin in patients with malignant pleural mesothelioma during treatment.
B. Grigoriu (2009)
Meta-analyses of studies of the diagnostic accuracy of laboratory tests: a review of the concepts and methods.
E. Vamvakas (1998)
10.1007/s12032-013-0543-6
Diagnostic value of mesothelin in pleural fluids: comparison with CYFRA 21-1 and CEA
R. Filiberti (2013)
10.1016/0895-4356(94)00099-C
Meta-analytic methods for diagnostic test accuracy.
L. Irwig (1995)
10.1164/rccm.200907-1020OC
Diagnostic performance of soluble mesothelin and megakaryocyte potentiating factor in mesothelioma.
K. Hollevoet (2010)
10.1016/j.clinbiochem.2009.03.007
Serum mesothelin has a higher diagnostic utility than hyaluronic acid in malignant mesothelioma.
B. Grigoriu (2009)
10.1016/j.lungcan.2011.01.011
Mesothelin and kidney function--analysis of relationship and implications for mesothelioma screening.
N. Boudville (2011)
10.1001/jama.1993.03510170086037
Users' guides to the medical literature.
G. Guyatt (1993)
10.1097/JTO.0b013e318180477b
Comparison of Osteopontin, Megakaryocyte Potentiating Factor, and Mesothelin Proteins as Markers in the Serum of Patients with Malignant Mesothelioma
J. Creaney (2008)
10.1007/s00408-013-9526-9
Serum Biomarkers in Patients with Mesothelioma and Pleural Plaques and Healthy Subjects Exposed to Naturally Occurring Asbestos
Mehmet Bayram (2013)
10.1148/RADIOL.2261021292
Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative.
P. Bossuyt (2003)
10.3978/j.issn.2072-1439.2013.03.03
The N-ERC index is a novel monitoring and prognostic marker for advanced malignant pleural mesothelioma.
T. Mori (2013)
10.1016/J.EJCDT.2013.04.005
Mesothelin and osteopontin as diagnostic and prognostic markers of malignant pleural mesothelioma in Egyptian patients undergoing pleurodesis
F. Amany (2013)
10.1515/CCLM.2011.242
Clinical significance of pleural effusion mesothelin in malignant pleural mesothelioma
S. Yamada (2011)
10.1002/9780470693926
Systematic Reviews in Health Care
M. Egger (2001)
10.1016/J.ATHORACSUR.2007.07.042
Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions.
H. Pass (2008)
10.1111/j.1349-7006.2007.00715.x
Aberrant splicing and protease involvement in mesothelin release from epithelioid mesothelioma cells
C. Sapede (2008)
10.1373/CLINCHEM.2006.079327
MESOMARK: a potential test for malignant pleural mesothelioma.
H. L. Beyer (2007)
10.1097/JTO.0b013e31821e1c08
Combined Serum Mesothelin and Plasma Osteopontin Measurements in Malignant Pleural Mesothelioma
A. Cristaudo (2011)
10.1155/2013/874212
Comparison of the Diagnostic Accuracy of the MSLN Gene Products, Mesothelin and Megakaryocyte Potentiating Factor, as Biomarkers for Mesothelioma in Pleural Effusions and Serum
J. Creaney (2013)
10.1183/09031936.00063109
Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma
A. Scherpereel (2009)
10.1158/1078-0432.CCR-06-2144
Utility of Osteopontin and Serum Mesothelin in Malignant Pleural Mesothelioma Diagnosis and Prognosis Assessment
B. Grigoriu (2007)
10.1111/j.1349-7006.2006.00246.x
Novel ELISA system for detection of N‐ERC/mesothelin in the sera of mesothelioma patients
K. Shiomi (2006)
10.1158/1078-0432.CCR-07-1613
Sensitive and Specific New Enzyme-Linked Immunosorbent Assay for N-ERC/Mesothelin Increases its Potential as a Useful Serum Tumor Marker for Mesothelioma
K. Shiomi (2008)
10.1002/SIM.4780121403
Combining independent studies of a diagnostic test into a summary ROC curve: data-analytic approaches and some additional considerations.
L. Moses (1993)
10.3109/07357907.2012.749265
Evaluation of Soluble Mesothelin-related Peptide as a Diagnostic Marker of Malignant Pleural Mesothelioma Effusions: Its Contribution to Cytology
P. Canessa (2013)
10.1158/1078-0432.CCR-10-1929
Serum Soluble Mesothelin Concentrations in Malignant Pleural Mesothelioma: Relationship to Tumor Volume, Clinical Stage and Changes in Tumor Burden
J. Creaney (2010)
10.1200/JCO.2011.39.6671
Serum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysis.
Kevin Hollevoet (2012)
10.1158/1055-9965.EPI-08-0422
Serum Levels of Soluble Mesothelin-Related Peptides in Malignant and Nonmalignant Asbestos-Related Pleural Disease: Relation with Past Asbestos Exposure
J. R. Portal (2009)
10.1016/J.EJCDT.2012.10.016
Combined blood and pleural levels of mesothelin and osteopontin for the diagnosis of malignant pleural mesothelioma
Wafaa M. Ashour (2012)
10.3892/ETM.2011.225
Feasibility of large-scale screening using N-ERC/mesothelin levels in the blood for the early diagnosis of malignant mesothelioma.
Kohta Imashimizu (2011)
10.1097/JTO.0b013e31820db377
Serial Measurements of Mesothelioma Serum Biomarkers in Asbestos-Exposed Individuals: A Prospective Longitudinal Cohort Study
K. Hollevoet (2011)
10.1016/j.lungcan.2012.12.008
Does CA125 binding to mesothelin impact the detection of malignant mesothelioma?
J. Creaney (2013)
Soluble mesothelin-related peptide and osteopontin as markers of response to treatment in malignant mesothelioma
P Wheatley-Price (2013)
10.1007/978-3-642-10862-4
[Malignant mesothelioma].
J. Espinosa Arranz (1994)
10.1111/J.2042-7166.2002.TB05479.X
Systematic Reviews in Health Care: Meta‐analysis in Context
M. Pittler (2010)
10.1515/CCLM.2010.066
Soluble mesothelin related peptides (SMRP) and osteopontin as protein biomarkers for malignant mesothelioma: analytical validation of ELISA based assays and characterization at mRNA and protein levels
A. Rai (2010)
10.1136/bmj.315.7109.629
Bias in meta-analysis detected by a simple, graphical test
M. Egger (1997)
10.1111/j.1440-1827.2006.02024.x
Molecular tumor markers for asbestos‐related mesothelioma: Serum diagnostic markers
M. Maeda (2006)
10.1158/1055-9965.EPI-07-0607
Profiling Tumor-Associated Markers for Early Detection of Malignant Mesothelioma: An Epidemiologic Study
M. Amati (2008)
10.1073/PNAS.93.1.136
Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers.
K. Chang (1996)
10.1016/J.LUNGCAN.2005.03.020
Soluble mesothelin-related protein--a blood test for mesothelioma.
B. Robinson (2005)
10.2217/bmm.11.18
Soluble markers for diagnosis of malignant pleural mesothelioma.
A. Cristaudo (2011)
10.1186/1471-2288-3-25
The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews
P. Whiting (2003)
10.1016/j.lungcan.2011.02.007
Plasma versus serum levels of osteopontin and mesothelin in patients with malignant mesothelioma--which is best?
J. Creaney (2011)
10.1183/09031936.00148211
A prospective trial evaluating the role of mesothelin in undiagnosed pleural effusions
C. Hooper (2012)
10.1515/CCLM.2007.112
Mesothelin family proteins and diagnosis of mesothelioma: analytical evaluation of an automated immunoassay and preliminary clinical results
F. di Serio (2007)
10.1186/1471-2288-2-9
Conducting systematic reviews of diagnostic studies: didactic guidelines
W. L. Devillé (2002)
10.1016/j.rmed.2009.05.017
Diagnostic value of soluble mesothelin-related peptides for malignant mesothelioma: a meta-analysis.
Ling Luo (2010)
10.1097/JTO.0b013e31824c9272
CCL2, Galectin-3, and SMRP Combination Improves the Diagnosis of Mesothelioma in Pleural Effusions
C. Blanquart (2012)
10.1097/JTO.0b013e3182272294
Soluble Mesothelin, Megakaryocyte Potentiating Factor, and Osteopontin as Markers of Patient Response and Outcome in Mesothelioma
K. Hollevoet (2011)
10.1111/j.1759-7714.2010.00001.x
Management of malignant pleural mesothelioma
P. Hürmüz (2010)
Users' Guides to the Medical Literature: A Manual for Evidence-Based Clinical Practice.
R. Graves (2002)
10.1200/JCO.2003.11.136
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.
N. Vogelzang (2003)
10.1016/j.lungcan.2007.12.025
Mesothelin-related predictive and prognostic factors in malignant mesothelioma: a nested case-control study.
O. Røe (2008)
10.1016/j.lungcan.2013.09.016
Pleural effusion hyaluronic acid as a prognostic marker in pleural malignant mesothelioma.
J. Creaney (2013)
BMJ Open
A Cui (2014)
10.1371/journal.pone.0072030
Hyaluronan and N-ERC/Mesothelin as Key Biomarkers in a Specific Two-Step Model to Predict Pleural Malignant Mesothelioma
Filip Mundt (2013)
10.1136/BMJ.323.7322.1188A
Systematic reviews of evaluations of diagnostic and screening tests
G. Ter Riet (2001)
10.5301/JBM.2011.8614
Biomarkers in Malignant Mesothelioma: Diagnostic and Prognostic Role of Soluble Mesothelin-Related Peptide
N. Dipalma (2011)
10.1016/j.medcli.2008.11.047
Pleural fluid mesothelin for the differential diagnosis of exudative pleural effusions.
C. Alemán (2009)
10.1016/S1556-0864(15)31535-5
Soluble Mesothelin Related Protein in Mesothelioma
J. Creaney (2006)
Mesothelin is more useful in pleural effusion than in serum in the diagnosis of pleural mesothelioma.
P. Ferro (2013)
10.3233/CBM-2007-3602
Soluble mesothelin-related peptides (SMRP) - high stability of a potential tumor marker for mesothelioma.
D. Weber (2007)
10.1111/j.1365-2702.2012.04122.x
Meta-analysis in context.
Z. Moore (2012)
10.1200/JCO.20005.14.589
Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada.
J. Van Meerbeeck (2005)
10.2165/00128415-200410260-00025
Diagnostic tests
D. Lewis (1995)
10.1378/chest.11-0129
The effect of clinical covariates on the diagnostic and prognostic value of soluble mesothelin and megakaryocyte potentiating factor.
Kevin Hollevoet (2012)
10.1515/cclm-2012-0314
A predictive equation to adjust for clinical variables in soluble mesothelin-related protein (SMRP) levels
E. Park (2012)
10.1164/rccm.200811-1729OC
Clinical impact and reliability of pleural fluid mesothelin in undiagnosed pleural effusions.
H. E. Davies (2009)
Diagnostic tests Users' guides to the medical literature. A manual for evidence-based clinical practice
R Jaeschke (2002)
10.1164/RCCM.200511-1789OC
Soluble mesothelin-related peptides in the diagnosis of malignant pleural mesothelioma.
A. Scherpereel (2006)
10.4161/epi.6.8.16074
The relationship between tumor MSLN methylation and serum mesothelin (SMRP) in mesothelioma
H. Nelson (2011)
10.1371/journal.pone.0018232
Association of MiR-126 with Soluble Mesothelin-Related Peptides, a Marker for Malignant Mesothelioma
L. Santarelli (2011)
10.1016/S0140-6736(03)14794-0
Mesothelin-family proteins and diagnosis of mesothelioma
B. Robinson (2003)
10.1158/1078-0432.CCR-06-0472
Megakaryocyte Potentiation Factor Cleaved from Mesothelin Precursor Is a Useful Tumor Marker in the Serum of Patients with Mesothelioma
M. Onda (2006)
10.1158/1055-9965.EPI-10-0346
Serum Mesothelin for Early Detection of Asbestos-Induced Cancer Malignant Mesothelioma
J. Creaney (2010)
10.1136/thx.2006.068114
Soluble mesothelin in effusions: a useful tool for the diagnosis of malignant mesothelioma
J. Creaney (2007)
10.1097/JTO.0b013e318187491c
Diagnostic and Prognostic Value of Soluble Mesothelin-Related Proteins in Patients with Malignant Pleural Mesothelioma in Comparison with Benign Asbestosis and Lung Cancer
J. Schneider (2008)
10.1038/bjc.2011.104
Markers for the non-invasive diagnosis of mesothelioma: a systematic review
S. van der Bij (2011)
10.1158/1078-0432.CCR-07-0629
Clinical Significance of Serum Mesothelin in Patients with Mesothelioma and Lung Cancer
A. Cristaudo (2007)
10.1183/09031936.00226111
Effectiveness of mesothelin family proteins and osteopontin for malignant mesothelioma
I. Pantazopoulos (2012)
10.1016/j.lungcan.2008.02.012
Megakaryocyte potentiating factor as a tumor marker of malignant pleural mesothelioma: evaluation in comparison with mesothelin.
K. Iwahori (2008)
Non-invasive diagnosis of pleural malignancies: the role of tumour markers. Lung Cancer 2008;59:350–4
MM van den Heuvel (2008)
10.1378/CHEST.07-0013
Combined CA125 and mesothelin levels for the diagnosis of malignant mesothelioma.
J. Creaney (2007)
10.1007/s00204-010-0580-2
Performance of biomarkers SMRP, CA125, and CYFRA 21-1 as potential tumor markers for malignant mesothelioma and lung cancer in a cohort of workers formerly exposed to asbestos
M. Gube (2010)



This paper is referenced by
10.2478/raon-2020-0011
Evaluation of Soluble Mesothelin-related Peptides and MSLN Genetic Variability in Asbestos-related Diseases
K. Goričar (2020)
10.21037/amj.2020.02.04
Malignant pleural effusion and mesothelioma
D. Subotic (2020)
10.1186/s40364-020-00194-4
Circulating long non-coding RNA GAS5 (growth arrest-specific transcript 5) as a complement marker for the detection of malignant mesothelioma using liquid biopsies
D. Weber (2020)
10.5772/intechopen.89438
Asbestos-Related Diseases and Blood Biomarkers
A. Franko (2019)
10.1183/16000617.0063-2016
Malignant pleural mesothelioma: an update on investigation, diagnosis and treatment
A. Bibby (2016)
10.18632/oncotarget.9686
Diagnostic value of microRNAs in asbestos exposure and malignant mesothelioma: systematic review and qualitative meta-analysis
Luigina Micolucci (2016)
10.21037/tlcr-19-488
Does size matter? -a population-based analysis of malignant pleural mesothelioma.
J. He (2020)
10.1136/thoraxjnl-2017-211321
British Thoracic Society Guideline for the investigation and management of malignant pleural mesothelioma
I. Woolhouse (2018)
10.1111/1759-7714.13746
Diagnostic value of microRNAs for malignant pleural mesothelioma: A mini‐review
Yan-qiu Han (2020)
10.1097/MD.0000000000014979
Diagnostic value of soluble mesothelin-related peptides in pleural effusion for malignant pleural mesothelioma
Ruiyue Gao (2019)
10.1373/jalm.2017.025015
Elevated Serum Megakaryocyte Potentiating Factor as a Predictor of Poor Survival in Patients with Mesothelioma and Primary Lung Cancer.
Y. Yu (2018)
10.21037/jtd.2017.10.88
Molecular markers and new diagnostic methods to differentiate malignant from benign mesothelial pleural proliferations: a literature review.
R. Bruno (2018)
10.1016/J.ARBRES.2014.06.005
Diagnóstico y tratamiento del mesotelioma pleural maligno
Francisco Rodríguez Panadero (2015)
10.1007/978-1-4471-2825-0_19
Malignant Mesothelioma: Molecular Markers
E. Kettunen (2014)
10.1136/bmjopen-2017-017104
Assessment of potential predictors of calretinin and mesothelin to improve the diagnostic performance to detect malignant mesothelioma: results from a population-based cohort study
S. Casjens (2017)
Chronic Inflammation in Malignant Mesothelioma Pathogenesis: Focus on HMGB1 Isoforms and Germline BAP1 Mutations
A. Napolitano (2015)
10.1007/s00408-016-9868-1
Evaluation of New Biomarkers in the Prediction of Malignant Mesothelioma in Subjects with Environmental Asbestos Exposure
Melike Demir (2016)
Development of more precise and efficient antibodies for cancer targeting : membrane associated form specific anti-mesothelin antibodies and CAR as an example
K. Asgarov (2016)
10.1007/978-3-319-53560-9_12
Biomarkers of Response to Asbestos Exposure
C. Mesaros (2017)
10.1117/1.JBO.23.10.105003
Diagnosis of malignant pleural mesothelioma from pleural fluid by Fourier transform-infrared spectroscopy coupled with chemometrics
S. Abbas (2018)
10.1016/J.RMCLC.2015.04.020
ASPECTOS DIAGNÓSTICOS Y TERAPÉUTICOS EN EL MESOTELIOMA PLEURAL MALIGNO
P. Rodriguez (2015)
10.3389/fonc.2020.537311
GPI-AP: Unraveling a New Class of Malignancy Mediators and Potential Immunotherapy Targets
Nada H. Hussein (2020)
10.21037/tlcr.2018.04.09
Breath analysis as a diagnostic and screening tool for malignant pleural mesothelioma: a systematic review.
Lisa Brusselmans (2018)
10.1016/j.freeradbiomed.2015.05.002
Malignant mesothelioma as an oxidative stress-induced cancer: An update.
S. H. Chew (2015)
10.1136/thoraxjnl-2014-206564
Author's response: Inconsistent results or inconsistent methods? A plea for standardisation of biomarker sampling in mesothelioma studies
J. Creaney (2014)
Malignant pleural mesothelioma : recognising an unmet need
Samal Gunatilake (2018)
10.1158/1078-0432.CCR-15-1130
HMGB1 and Its Hyperacetylated Isoform are Sensitive and Specific Serum Biomarkers to Detect Asbestos Exposure and to Identify Mesothelioma Patients
A. Napolitano (2016)
10.18632/oncotarget.13174
Malignant pleural mesothelioma and mesothelial hyperplasia: A new molecular tool for the differential diagnosis
R. Bruno (2017)
10.1080/19420862.2017.1288770
A new anti-mesothelin antibody targets selectively the membrane-associated form
K. Asgarov (2017)
10.18632/oncotarget.17436
Prognostic significance of soluble mesothelin in malignant pleural mesothelioma: a meta-analysis
Long Tian (2017)
10.1177/1753465816671697
Current best practice in the evaluation and management of malignant pleural effusions
S. Walker (2017)
10.1177/1753466618808660
Biomarkers in the diagnosis of pleural diseases: a 2018 update
J. M. Porcel (2018)
See more
Semantic Scholar Logo Some data provided by SemanticScholar